Pharmaceutical Product Monograph: Dacarbazine for Injection (200 mg, 500 mg)
In the pharmaceutical industry, Dacarbazine (DTIC) is a parenteral, non-classical Alkylating Agent. As a pharmacist and manufacturer, I view this molecule as a “Methylating Pro-drug”—it is technically designed to be activated by the liver into a potent DNA-damaging compound that specifically targets rapidly dividing cancer cells.
At your WHO-GMP facility in Mumbai, Dacarbazine is a core SKU for Oncology and Specialty Care portfolios. It remains a foundational treatment for specific solid tumors and hematological malignancies, often used in combination with other cytotoxic agents.
Therapeutic Profile: Primary Indications
Dacarbazine is primarily indicated for two major types of cancer where it has shown significant clinical efficacy.
| Indication | Clinical Context | Technical Rationale |
| Metastatic Melanoma | Skin Cancer | Gold Standard: Historically the primary chemotherapy for advanced melanoma, often used when immunotherapy is not an option. |
| Hodgkin Lymphoma | ABVD Regimen | A critical component of the “D” in the ABVD protocol (Adriamycin, Bleomycin, Vinblastine, Dacarbazine). |
| Soft Tissue Sarcoma | Solid Tumors | Used in the treatment of various sarcomas (like leiomyosarcoma) when they become resistant to first-line agents. |
| Islet Cell Carcinoma | Pancreatic Cancer | Sometimes used for malignant glucagonomas or other neuroendocrine tumors. |
Mechanism: DNA Alkylation & Methylation
Dacarbazine works by sabotaging the “blueprint” of the cancer cell:
Hepatic Activation: Dacarbazine is a pro-drug. It must be technically metabolized in the liver by Cytochrome P450 enzymes into its active form, MTIC (monomethyl triazeno imidazole carboxamide).
Methyl Group Transfer: MTIC acts as an alkylating agent, transferring a methyl group to the DNA of the cancer cell, specifically at the $O^6$ and $N^7$ positions of guanine.
Cross-linking & Death: This methylation prevents DNA strands from unzipping or replicating correctly. The cell recognizes the DNA damage and triggers Apoptosis (programmed cell death).
The Pharmacist’s “Technical Warning”
The “Emetic” Profile: As a pharmacist, I must emphasize that Dacarbazine is Highly Emetogenic. Almost 90% of patients experience severe nausea and vomiting. Pre-treatment with strong 5-HT3 antagonists (like Ondansetron) and steroids is technically mandatory.
Photosensitivity: Dacarbazine is extremely sensitive to light. During administration, the IV bag and tubing must be covered with light-resistant (amber) foil. If the solution turns pink, it has degraded and must be discarded.
Extravasation Risk: It is a potent vesicant/irritant. If the IV leaks into the surrounding tissue, it can cause severe pain and tissue damage. Always ensure a “flashback” in the IV line before starting.
Bone Marrow Suppression: Significant drops in white blood cells and platelets usually occur 2–4 weeks after the dose. Blood counts must be monitored strictly before every cycle.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilization” USP: On your digital marketplace, highlight your High-Containment Lyophilized Cake. Dacarbazine is unstable in liquid form; your vacuum-drying process ensures a stable 24-month shelf life.
The “Hazardous Drug” Protocol: For international B2B buyers, emphasize that your facility uses Isolator Technology for filling. This ensures zero cross-contamination and protects both the product and the operators from cytotoxic exposure.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Dacarbazine 200 mg and 500 mg vials to support your registration in international B2B oncology tenders.